Mr. Ross joined Enovis (then known as Colfax) in 2012 as GM of Colfax Reliability Services and has held
numerous leadership roles, including Investor Relations, Strategy & Business Development, and President of the Companys Recovery Sciences and Bracing and Support Businesses. Prior to joining the Company, he served in management
roles at Danaher and GE.
Mr. Vogt joined DJO (now Enovis) in 2017, leading the Surgical Global Product Management and US Sales Organizations before
becoming President of the Enovis U.S. surgical business. Prior to joining the Company, he spent 15 years with Zimmer and Zimmer Biomet in a series of U.S. and Global Marketing, Product Management and Commercial leadership roles.
About Enovis
Enovis Corporation (NYSE: ENOV) is an
innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent
and innovation, the Companys extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.
Forward-Looking Statements
This press release includes
forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis
plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis current expectations and involve risks and uncertainties that could
cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis results to differ materially from current expectations include, but are not limited to, the risks and
other factors detailed in Enovis reports filed with the U.S. Securities and Exchange Commission (the SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q under the caption Risk Factors, as well as the other risks discussed in Enovis filings with the SEC. In addition, these statements are based on assumptions that are
subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Contact:
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
+1-917-734-7450
investorrelations@enovis.com